Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535mIpsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a Share XIpsen adds Blueprint’s FOP rare disease drug to pipeline for $535mhttps://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
AZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewThe FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, Share XAZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewhttps://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/
Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialEli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a Share XLilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialhttps://pharmaphorum.com/news/lillys-1-6bn-cancer-drug-draws-blank-in-pancreatic-cancer-trial/
Roche sets analysts purring with strong Q3 resultsRoche has beaten market expectations in third quarter results, with new drugs gaining traction and its older medicines Share XRoche sets analysts purring with strong Q3 resultshttps://pharmaphorum.com/news/roche-sets-analysts-purring-with-strong-q3-results/
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techLA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that Share XImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techhttps://pharmaphorum.com/news/imaginab-joins-with-az-pfizer-and-takeda-to-develop-tumour-imaging-tech/
New price gets Clovis’ PARP inhibitor on the CDFNICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to Share XNew price gets Clovis’ PARP inhibitor on the CDFhttps://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/
GSK joins with US biotech to toughen up cell therapies for solid tumoursGlaxoSmithKline has announced a five-year collaboration with San Francisco biotech Lyell Immunopharma, to strengthen therapeutic T-cells before they Share XGSK joins with US biotech to toughen up cell therapies for solid tumourshttps://pharmaphorum.com/news/gsk-joins-with-us-biotech-to-toughen-up-cell-therapies-for-solid-tumours/
Owkin’s machine learning tech to inform mesothelioma trialsA mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and Share XOwkin’s machine learning tech to inform mesothelioma trialshttps://pharmaphorum.com/news/owkins-machine-learning-tech-gives-mesothelioma-prognosis-and-survival-insights/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
